Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A

Haemophilia

Volumn 19, Issue 1, 2013, Pages 106-112

  Klintman, J ^a   Hillarp, A ^a   Donfield, S ^b   Berntorp, E ^a   Astermark, J ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b RHO INC   (United States)

Author keywords

Antibody specificity; Factor VIII; Haemophilia A; Immune tolerance induction; Non neutralizing antibodies

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOLOGICAL TOLERANCE; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; INFANT; MALE; MIDDLE AGED; SIBLINGS; YOUNG ADULT;

EID: 84871012263     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02903.x     Document Type: Article

References (26)

1. Dazzi F, Tison T, Vianello F et al. High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Br J Haematol 1996; 93: 688-93.
2. Gilles JG, Arnout J, Vermylen J, Saint-Remy JM. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452-61.
3. Ling M, Duncan EM, Rodgers SE, Street AM, Lloyd JV. Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay. J Thromb Haemost 2003; 1: 2548-53.
4. Mondorf W, Klinge J, Luban NL et al. Low factor VIII recovery in haemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay. Haemophilia 2001; 7: 13-9.
5. Nilsson IM, Berntorp E, Zettervall O, Dahlbäck B. Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients. Blood 1990; 75: 378-83.
6. Scandella D, Mondorf W, Klinge J. The natural history of the immune response to exogenous factor VIII in severe haemophilia A. Haemophilia 1998; 4: 546-51.
7. Vianello F, Radossi P, Tison T et al. Prevalence of anti-FVIII antibodies in severe haemophilia A patients with inversion of intron 22. Br J Haematol 1997; 97: 807-9.
8. Di Giambattista M, Branckaert T, Hougardy V, Kemball-Cook G, Laub R. In silico prediction of FVIII epitopes recognised by natural autoantibodies in polyvalent immunoglobulin concentrates. Mol Immunol 2007; 44: 1903-13.
9. Gilles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest 1994; 94: 1496-505.
10. Jacquemin MG, Saint-Remy JM. Factor VIII immunogenicity. Haemophilia 1998; 4: 552-7.
11. Batlle J, Gomez E, Rendal E et al. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. Ann Hematol 1996; 72: 321-6.
12. Krudysz-Amblo J, Parhami-Seren B, Butenas S et al. Quantitation of anti-factor VIII antibodies in human plasma. Blood 2009; 113: 2587-94.
13. Lebreton A, Lapalud P, Chambost H et al. Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors. Thromb Haemost 2011; 105: 1-8.
14. Vincent AM, Lillicrap D, Boulanger A et al. Non-neutralizing anti-FVIII antibodies: different binding specificity to different recombinant FVIII concentrates. Haemophilia 2009; 15: 374-6.
15. Zakarija A, Harris S, Rademaker AW et al. Alloantibodies to factor VIII in haemophilia. Haemophilia 2011; 17: 636-40.
16. Kempton CL, Meeks SL, Donald Harvey R, Abshire TC. Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII. Haemophilia 2011; 17: 155-6.
17. Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-33.
18. van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010; 69: 1554-61.
19. Astermark J, Berntorp E, White GC, Kroner BL, Group MS. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
20. Berntorp E, Astermark J, Donfield SM, Nelson GW, Oldenburg J et al. Haemophilia Inhibitor Genetics Study - evaluation of a model for studies of complex diseases using linkage and association methods. Haemophilia 2005; 11: 427-9.
21. Kasper CK, Aledort L, Aronson D et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
22. Kasper CK, Pool JG. Letter: measurement of mild factor VIII inhibitors in Bethesda units. Thromb Diath Haemorrh 1975; 34: 875-6.
23. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
24. Astermark J, Oldenburg J, Escobar M, White GC 2nd, Berntorp E. The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005; 90: 924-31.
25. Oldenburg J. Mutation profiling in haemophilia A. Thromb Haemost 2001; 85: 577-9.
26. Caram C, de Souza RG, de Sousa JC et al. The long-term course of factor VIII inhibitors in patients with congenital haemophilia A without immune tolerance induction. Thromb Haemost 2011; 105: 59-65.